One patient who received PEG-IFN-α-2b plus TAF therapy suffered with ascites at 40 weeks post therapy, and discontinued PEG-IFN-α-2b therapy based on the consultation of supervising doctors. The gene discussed is IFNA1; the disease is Ascites.